Top 10 Pharmaceutical Stocks with Highest Upside: HRBR, ARYX, PRAN, XOMA, DARA, CXM, CBRX, BIOD, CYTR, ANX (Jul 12, 2010)
"Strong Buy" Rated U.S.-Listed Chinese Stocks (February 8, 2012)
Below are the top 10 Pharmaceutical stocks with highest upside potential, based on the difference between current price and Wall Street analysts' average target price.
Harbor BioSciences, Inc. (NASDAQ:HRBR) has the 1st highest upside potential in this segment of the market. Its upside is 2339.0%. Its consensus target price is $6.00 based on the average of all estimates. ARYx Therapeutics, Inc. (NASDAQ:ARYX) has the 2nd highest upside potential in this segment of the market. Its upside is 1275.0%. Its consensus target price is $5.50 based on the average of all estimates. Prana Biotechnology Limited (ADR) (NASDAQ:PRAN) has the 3rd highest upside potential in this segment of the market. Its upside is 501.5%. Its consensus target price is $8.00 based on the average of all estimates. XOMA Limited (NASDAQ:XOMA) has the 4th highest upside potential in this segment of the market. Its upside is 433.4%. Its consensus target price is $1.98 based on the average of all estimates. DARA BioSciences, Inc. (NASDAQ:DARA) has the 5th highest upside potential in this segment of the market. Its upside is 416.1%. Its consensus target price is $16.00 based on the average of all estimates.
Cardium Therapeutics Inc. (NYSE:CXM) has the 6th highest upside potential in this segment of the market. Its upside is 348.0%. Its consensus target price is $1.50 based on the average of all estimates. Columbia Laboratories Inc. (NASDAQ:CBRX) has the 7th highest upside potential in this segment of the market. Its upside is 300.0%. Its consensus target price is $4.00 based on the average of all estimates. Biodel Inc (NASDAQ:BIOD) has the 8th highest upside potential in this segment of the market. Its upside is 295.8%. Its consensus target price is $15.00 based on the average of all estimates. CytRx Corporation (NASDAQ:CYTR) has the 9th highest upside potential in this segment of the market. Its upside is 273.1%. Its consensus target price is $2.50 based on the average of all estimates. ADVENTRX Pharmaceuticals, Inc. (AMEX:ANX) has the 10th highest upside potential in this segment of the market. Its upside is 265.9%. Its consensus target price is $6.00 based on the average of all estimates.
